The specialists. The scans. The medications. The injections. You did all of it, in the order you were told, and you are still in pain — now carrying an additional weight that nobody says out loud but that you can feel in the room: the quiet implication that maybe the problem is you.
It is not. And the reason it is not has nothing to do with how hard you tried.
The model was designed to manage you, not heal you
Standard pain management did not fail because of you. It failed because of what it was built to do.
Read the name of the specialty literally. Pain management. The word describes an ongoing state to be administered, not a condition to be resolved. That is not an accident of terminology — it reflects the architecture. The model is organized around controlling a symptom over time: adjusting doses, scheduling repeat procedures, monitoring, titrating, maintaining.
A framework built to manage something will manage it. It will do so competently, with skilled clinicians and defensible decisions at every step. What it will not do is resolve the thing, because resolution was never the target it was optimized for.
That is why your experience of the pathway probably felt like motion without arrival. There was always a next step. There was rarely an endpoint.
The frontline tools are weaker than advertised
There is a second problem, and it is more specific: the tools the model leans on hardest do not perform the way their prominence implies.
On opioids. In the landmark SPACE trial, opioids produced no better function than non-opioid care, with more harm. That is a striking result for a class of medication that occupied the center of chronic pain treatment for decades. Not modestly better with more risk — no better on function, and more harm.
On repeated steroids. Repeated steroids lost more cartilage than placebo. Again, the comparison is against an inert control, and again the finding runs against the assumption that the intervention is at worst neutral.
These are the two tools the model leans on hardest. They are what you were most likely offered, most likely repeatedly. If the frontline of a treatment model underperforms against its own controlled comparisons, then a patient who follows that model faithfully and does not improve has not deviated from anything. They have received exactly what the model provides.
Why the map was the problem
Here is the useful way to think about your own history. You were not navigating badly. You were navigating accurately with a map that did not include the terrain you were standing on.
The map the standard model uses locates pain in a structure — a disc, a joint, a nerve — and directs interventions at that location. Every step you took followed it correctly. The specialists you saw were reading it correctly. The problem is that the map omits an entire category of driver, and if your pain originates in the omitted category, no amount of skilled navigation gets you anywhere.
That omitted category is the metabolic terrain. It is not on the map because the model was not built to look for it, so nobody at any point in your journey was structurally required to measure it. Not because of negligence — because it is not part of the framework they are working within.
What a root-cause framework targets instead
The alternative is not a better version of the same sequence. It is a different question at the outset.
Rather than asking which structure to target next, a root-cause framework asks what is generating and sustaining the pain — and treats the metabolic terrain driving it as a measurable, addressable target rather than as background noise. That reordering has consequences. Assessment comes before intervention. Measurement comes before procedures. And the interventions that follow are aimed at the driver rather than at the loudest expression of it.
It is slower at the start and it asks more of you at the front end. What it offers in exchange is the possibility of an endpoint — which is the one thing the management model, by its own design, was never structured to provide.
If you have been through the standard pathway without resolution, the question worth bringing to a physician is not what to try next on the same list. It is whether anyone has ever looked at the variable the list does not contain.
Frequently asked questions
Should I stop the treatments I am currently on?
No. Do not start, stop, or change any treatment without consulting your physician — and this is especially important with medications that require supervised adjustment. Bring these questions to the physician managing your care, or seek a formal evaluation. Nothing here is a directive to discontinue anything on your own.
Does the SPACE trial mean opioids are never appropriate?
The trial finding, as described, is specific: opioids produced no better function than non-opioid care, with more harm. That is a comparison of treatment strategies for chronic pain, and it argues against opioids as a frontline strategy for this population. Decisions about your own medication belong with the physician prescribing it.
If it is not my fault, why do I feel like everyone thinks it is?
Because when a model has applied its full sequence and the patient has not improved, the only variable the model has left to question is the patient. That is a limitation of the framework, not an assessment of you. A framework that cannot see a driver will attribute unexplained failure to whatever it can see.
What does a root-cause evaluation actually measure?
It looks at the metabolic terrain driving the pain — the variable a structure-focused pathway is not built to capture — alongside the structural assessment. Individual results vary and not every patient is a candidate for every approach; what is relevant to your case is determined by evaluation, not by an article.
Key takeaways
- The standard model was designed to manage pain over time, not to resolve it, and it performs that function as designed.
- In the landmark SPACE trial, opioids produced no better function than non-opioid care, with more harm.
- Repeated steroids lost more cartilage than placebo — and these are the two tools the model relies on most.
- The metabolic terrain driving pain is not on the standard map, so it is never structurally required to be measured.
- A root-cause framework measures first and targets the driver, which is what makes an endpoint possible.
Medically reviewed by Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.
This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary, and not every patient is a candidate for the therapies described. Do not start, stop, or change any treatment without consulting your physician.
Find out what is actually driving your pain
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call (314) 295-3000 or text (314) 886-5902.